The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.

Publication

The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.

Journal Paper/Review - Apr 15, 2007

Horger Marius, Kanz Lothar, Denecke Barbara, Vonthein Reinhard, Pereira Philippe, Claussen Claus Detlef, Driessen Christoph

Citation

Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-26.

Type

Journal Paper/Review (English)

Journal

Cancer 2007; 109

Publication Date

Apr 15, 2007

Issn Print

0008-543X

Pages

1617-26

Brief description/objective

The objectives of this study were to assess the status and clinical course of patients with multiple myeloma based on the direct visualization of changes in medullary, extramedullary, and focal osteolytic myeloma involvement by using whole-body, low-dose, multidetector computed tomography (WBLD-MDCT) and to compare those results with an assessment based on conventional hematologic parameters.